By contrast, we’ve confirmed that cyclopamine treatment at e12.5 will not influence interneuron destiny specification significantly, recommending that Shh morphogenic […]
Targeting FLT3 for Cancer therapy
FLT3 inhibitors
By contrast, we’ve confirmed that cyclopamine treatment at e12.5 will not influence interneuron destiny specification significantly, recommending that Shh morphogenic […]